Are you need IT Support Engineer? Free Consultant
Global Precision Oncology Diagnostics Market Outlook 2034: Global Opportunity and Demand Analysis, Market Forecast to 2034
- Published :
Report ID: HC0105
Pages: 169
Base Year: 2025
Format: PDF
Historical Date: 2020-2024
Market Research Report
Summary At A Glance
Description
Table of Contents
List Of Tables
List Of Figures
Research Methodology
Description
MARKET OVERVIEW:
The Precision Oncology Diagnostics Market occupies a strategic space at the intersection of advanced molecular technologies and personalized cancer care, offering clinicians tools to deliver targeted therapies and improve patient outcomes. Precision oncology diagnostics encompass tests that assess genomic, proteomic, and molecular tumor profiles, enabling treatment selection, disease monitoring, and early relapse detection.
The market is projected to grow at a CAGR of approximately 8.5% from 2026 to 2034, reflecting rising adoption of genomic sequencing, liquid biopsy platforms, and biomarker-driven panels. Key trends shaping the market include:
- Rising global cancer burden due to aging populations, lifestyle changes, and environmental factors, driving the need for early, precise, and minimally invasive diagnostics.
- Integration of AI and machine learning into diagnostic interpretation, improving accuracy, reducing turnaround times, and enabling large-scale molecular profiling.
- Value-based care models that emphasize cost-efficient diagnostics with direct therapeutic implications, encouraging adoption across hospitals and research institutions.
These trends collectively position precision oncology diagnostics as a fast-growing pillar of the broader precision medicine landscape, supporting clinicians, patients, and pharmaceutical development alike.
MARKET DYNAMICS:
Driver: Widespread Adoption of Genomic and Liquid Biopsy Technologies
Technological innovations such as next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) assays are transforming oncology care. Liquid biopsy technologies, in particular, offer non-invasive, real-time monitoring of tumor progression, enabling early detection of mutations and minimal residual disease. The growing availability of multi-gene panels and comprehensive genomic assays further accelerates adoption across clinical and research settings.
Restraint: High Cost and Reimbursement Barriers
Despite their clinical advantages, precision oncology diagnostics remain cost-prohibitive, particularly in regions with limited healthcare funding. Reimbursement policies for advanced tests are fragmented across geographies, with coverage gaps slowing adoption in emerging markets and smaller laboratory networks.
Opportunity: Integration of AI and Digital Pathology
The integration of AI-based analytics and digital pathology platforms represents a significant growth opportunity. AI tools enhance histopathological accuracy, enable automated tumor subtyping, and streamline workflows. For example, in May 2026, Roche acquired PathAI for USD 750 million, strengthening its precision oncology pipeline through AI-driven pathology and predictive analytics.
SEGMENTATION ANALYSIS:
The Diagnostic Technology – Liquid Biopsy and Genomic Sequencing is anticipated to grow significantly during the forecast period
Among diagnostic technologies, liquid biopsy and genomic sequencing platforms are emerging as high‑growth categories. Liquid biopsies, which analyze circulating tumor DNA from blood samples, enable clinicians to detect actionable mutations without invasive tissue biopsies. Their increasing clinical validation and favorable patient profiles position them as a cornerstone of precision oncology diagnostics. These platforms support recurrent monitoring, which can detect minimal residual disease and early relapse—capabilities that traditional imaging often misses.
Genomic sequencing systems, especially next‑generation sequencing (NGS), provide comprehensive insights into tumor genomes, enabling multi‑gene panels that inform tailored treatment regimens. The integration of NGS data into clinical decision support systems is further improving diagnostic accuracy and expanding test utilization across oncology care settings.
End-Use – Hospitals & Diagnostic Laboratories
Hospitals and diagnostic laboratories constitute the largest end-use market, integrating precision diagnostics directly into oncology care pathways. High-throughput sequencing and liquid biopsy testing are increasingly used to guide surgical, chemotherapeutic, and immunotherapy decisions. Collaborative networks between diagnostics providers and hospitals are expanding decentralized testing capabilities, enhancing access and reducing turnaround times, particularly in regions with advanced oncology infrastructure.
REGIONAL ANALYSIS:
North America dominates the precision oncology diagnostics market
North America dominates the precision oncology diagnostics market, benefiting from robust healthcare infrastructure, early adoption of advanced diagnostics, and favorable reimbursement policies. The U.S. is the largest national market, driven by both clinical and research applications.
Meanwhile, Asia-Pacific is the fastest-growing region, propelled by increasing government healthcare investments, expansion of oncology services, and growing awareness of precision medicine. Countries such as China, India, and Japan are expected to see accelerated adoption of genomic and liquid biopsy technologies, supported by rising cancer incidence and expanding clinical infrastructure.
COMPETITIVE ANALYSIS:
The competitive landscape is shaped by global diagnostics and biotech leaders. Roche Diagnostics, Illumina, Guardant Health, and QIAGEN are at the forefront, offering comprehensive genomic platforms, liquid biopsy tests, and companion diagnostics. Market competition is driven by:
- Strategic acquisitions and partnerships to enhance AI-driven capabilities and diagnostic pipelines
- Expansion of geographic presence to reach emerging markets and research institutions
- Development of reimbursable, high-throughput, and patient-centric diagnostic solutions
See some of the major key players in the market.
- Roche Diagnostics
- Guardant Health, Inc.
- TEMPUS Labs
- Caris Life Sciences
- Illumina, Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- AstraZeneca plc
- Novartis AG
- Myriad Genetics, Inc.
Recent Development:
- May 2026: Roche agreed to acquire U.S. digital pathology and AI specialist PathAI for USD 750 million, enhancing its precision oncology diagnostics capabilities through automated histopathology and machine learning analytics
- January 2026: Illumina announced that the Centers for Medicare & Medicaid Services (CMS) granted reimbursement coverage for its FDA‑approved TruSight Oncology Comprehensive test, broadening access to comprehensive genomic profiling and supporting wider adoption of precision oncology testing in clinical practice
SCOPE OF THE REPORT:
- By Diagnostic Technology
- Genomic Sequencing
- Liquid Biopsy
- Immunoassays & Biomarker Panels
- Molecular Imaging
- By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Others
- By End‑Use
- Hospitals & Diagnostic Laboratories
- Research Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- By Region
- North America (United States & Canada)
- Europe (Germany, UK, France, Spain, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, India, South Korea, Australia and Rest of Asia-Pacific)
- Latin America (Brazil, Mexico, Argentina and Rest of Latin America)
- Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa and Rest of Middle East and Africa)
KEY REASONS TO PURCHASE THIS REPORT:
- In‑depth segmentation analysis across diagnostic technology, cancer types, end‑use segments, and regions to guide strategic investment decisions
- Comprehensive market forecasting through 2034 with detailed revenue and CAGR projections to support long‑term planning
- Competitive benchmarking and strategic insights highlighting key players, market entry strategies, and recent M&A or technology developments
- Actionable intelligence on emerging trends such as liquid biopsy adoption, AI in diagnostics, and reimbursement dynamics
- Regional and country‑level analysis enabling tailored go‑to‑market strategies for North America, Europe, Asia‑Pacific, Latin America, and MEA
Table of Contents
- Executive Summary
1.1. Global Precision Oncology Diagnostics Market Outlook
1.1.1. Global Precision Oncology Diagnostics Market – Regional Analysis
1.1.2. Global Precision Oncology Diagnostics Market – Segment Analysis
1.2. Technology Roadmap Analysis - Overview And Scope
2.1. Market Coverage
2.2. Market Definition
2.3. Market Segmentation
- By Diagnostic Technology
- By Cancer Type
- By End-Use
- By Region
- Global Precision Oncology Diagnostics Market Overview, By Region: 2020 Vs 2026 Vs 2034
3.1. Global Precision Oncology Diagnostics Market, By Region (2020 Vs 2026 Vs 2034)
3.2. North America Market, By Country (2020 Vs 2026 Vs 2034)
3.3. Europe Market, By Country (2020 Vs 2026 Vs 2034)
3.4. Asia-Pacific Market, By Country (2020 Vs 2026 Vs 2034)
3.5. Latin America Market, By Country (2020 Vs 2026 Vs 2034)
3.6. Middle East & Africa Market, By Country (2020 Vs 2026 Vs 2034) - Global Precision Oncology Diagnostics Market Dynamics
4.1. Market Overview
4.1.1. Market Drivers
4.1.1.1. Widespread Adoption of Genomic and Liquid Biopsy Technologies
4.1.1.2. AI Integration in Diagnostics for Enhanced Accuracy
4.1.2. Market Restraints/Challenges Analysis
4.1.2.1. High Cost and Reimbursement Barriers
4.1.2.2. Fragmented Coverage Across Geographies
4.1.3. Market Opportunities
4.1.3.1. Digital Pathology and AI Analytics
4.1.3.2. Expansion in Emerging Markets
4.2. PESTLE Analysis
4.3. Value Chain Analysis/Supply Chain Analysis
4.4. Porter’s Five Forces Model
4.5. Regulatory Landscape - Global Precision Oncology Diagnostics Market, By Diagnostic Technology
5.1. Introduction / Key Findings
5.2. Global Market By Diagnostic Technology (2020–2034) (USD Million)
5.3. Key Findings – By Diagnostic Technology
5.3.1. Genomic Sequencing
5.3.2. Liquid Biopsy
5.3.3. Immunoassays & Biomarker Panels
5.3.4. Molecular Imaging - Global Precision Oncology Diagnostics Market, By Cancer Type
6.1. Overview
6.2. Global Market By Cancer Type (2020–2034) (USD Million)
6.3. Key Findings – By Cancer Type
6.3.1. Breast Cancer
6.3.2. Lung Cancer
6.3.3. Colorectal Cancer
6.3.4. Others - Global Precision Oncology Diagnostics Market, By End-Use
7.1. Overview
7.2. Global Market By End-Use (2020–2034) (USD Million)
7.3. Key Findings – By End-Use
7.3.1. Hospitals & Diagnostic Laboratories
7.3.2. Research Institutes & Academic Centers
7.3.3. Pharmaceutical & Biotechnology Companies
7.3.4. Contract Research Organizations (CROs) - Global Precision Oncology Diagnostics Market, By Region
8.1. Overview
8.2. Global Market, By Region (2020–2034) (USD Million)
8.3. Key Findings – By Region
8.4. Global Market, By Diagnostic Technology
8.5. Global Market, By Cancer Type
8.6. Global Market, By End-Use - Global Precision Oncology Diagnostics Market – North America
9.1. Overview
9.2. North America Market (2020–2034) (USD Million)
9.3. North America Market, By Diagnostic Technology
9.4. North America Market, By Cancer Type
9.5. North America Market, By End-Use
9.6. North America Market, By Country
9.6.1. United States
9.6.2. Canada - Global Precision Oncology Diagnostics Market – Europe
10.1. Overview
10.2. Europe Market (2020–2034) (USD Million)
10.3. Europe Market, By Diagnostic Technology
10.4. Europe Market, By Cancer Type
10.5. Europe Market, By End-Use
10.6. Europe Market, By Country
10.6.1. Germany
10.6.2. UK
10.6.3. France
10.6.4. Spain
10.6.5. Italy
10.6.6. Rest of Europe - Global Precision Oncology Diagnostics Market – Asia-Pacific
11.1. Overview
11.2. Asia-Pacific Market (2020–2034) (USD Million)
11.3. Asia-Pacific Market, By Diagnostic Technology
11.4. Asia-Pacific Market, By Cancer Type
11.5. Asia-Pacific Market, By End-Use
11.6. Asia-Pacific Market, By Country
11.6.1. China
11.6.2. Japan
11.6.3. India
11.6.4. South Korea
11.6.5. Australia
11.6.6. Rest of Asia-Pacific - Global Precision Oncology Diagnostics Market – Latin America
12.1. Overview
12.2. Latin America Market (2020–2034) (USD Million)
12.3. Latin America Market, By Diagnostic Technology
12.4. Latin America Market, By Cancer Type
12.5. Latin America Market, By End-Use
12.6. Latin America Market, By Country
12.6.1. Brazil
12.6.2. Mexico
12.6.3. Argentina
12.6.4. Rest of Latin America - Global Precision Oncology Diagnostics Market – Middle East & Africa
13.1. Overview
13.2. Middle East & Africa Market (2020–2034) (USD Million)
13.3. Middle East & Africa Market, By Diagnostic Technology
13.4. Middle East & Africa Market, By Cancer Type
13.5. Middle East & Africa Market, By End-Use
13.6. Middle East & Africa Market, By Country
13.6.1. Saudi Arabia
13.6.2. UAE
13.6.3. Israel
13.6.4. South Africa
13.6.5. Rest of Middle East & Africa - Global Precision Oncology Diagnostics Market – Competitive Landscape
14.1. Key Competitive Analysis
14.2. Key Strategies Adopted by Leading Players
14.3. Competitive Positioning
14.3.1. Important Performers
14.3.2. Emerging Innovators
14.3.3. Moderate Innovation Players
14.4. Recent Developments (2025–2026) - Global Precision Oncology Diagnostics Market – Company Profiles
15.1. Roche Diagnostics
- Corporate Summary
- Corporate Financial Review
- Product Portfolio
- Key Developments
15.2. Guardant Health, Inc.
15.3. TEMPUS Labs
15.4. Caris Life Sciences
15.5. Illumina, Inc.
15.6. QIAGEN N.V.
15.7. Thermo Fisher Scientific Inc.
15.8. AstraZeneca plc
15.9. Novartis AG
15.10. Myriad Genetics, Inc.
- Research Methodology
16.1. Our Research Practice
16.2. Data Source
16.2.1. Secondary Source
16.2.2. Primary Source
16.3. Data Assumptions
16.4. Analytical Framework for Market Assessment and Forecasting
16.5. Our Research Process
16.6. Data Validation and Publishing (Secondary Source) - Appendix
17.1. Disclaimer
17.2. Contact Us
List Of Tables
Table 1 Global Precision Oncology Diagnostics Market, By Diagnostic Technology (2020–2027) (USD Million)
Table 2 Global Precision Oncology Diagnostics Market, By Diagnostic Technology (2028–2034) (USD Million)
Table 3 Global Precision Oncology Diagnostics Market, By Cancer Type (2020–2027) (USD Million)
Table 4 Global Precision Oncology Diagnostics Market, By Cancer Type (2028–2034) (USD Million)
Table 5 Global Precision Oncology Diagnostics Market, By End-Use (2020–2027) (USD Million)
Table 6 Global Precision Oncology Diagnostics Market, By End-Use (2028–2034) (USD Million)
Table 7 Global Precision Oncology Diagnostics Market, By Diagnostic Technology – Genomic Sequencing (2020–2027) (USD Million)
Table 8 Global Precision Oncology Diagnostics Market, By Diagnostic Technology – Genomic Sequencing (2028–2034) (USD Million)
Table 9 Global Precision Oncology Diagnostics Market, By Diagnostic Technology – Liquid Biopsy (2020–2027) (USD Million)
Table 10 Global Precision Oncology Diagnostics Market, By Diagnostic Technology – Liquid Biopsy (2028–2034) (USD Million)
Table 11 Global Precision Oncology Diagnostics Market, By Diagnostic Technology – Immunoassays & Biomarker Panels (2020–2027) (USD Million)
Table 12 Global Precision Oncology Diagnostics Market, By Diagnostic Technology – Immunoassays & Biomarker Panels (2028–2034) (USD Million)
Table 13 Global Precision Oncology Diagnostics Market, By Diagnostic Technology – Molecular Imaging (2020–2027) (USD Million)
Table 14 Global Precision Oncology Diagnostics Market, By Diagnostic Technology – Molecular Imaging (2028–2034) (USD Million)
Table 15 Global Precision Oncology Diagnostics Market, By Cancer Type – Breast Cancer (2020–2027) (USD Million)
Table 16 Global Precision Oncology Diagnostics Market, By Cancer Type – Breast Cancer (2028–2034) (USD Million)
Table 17 Global Precision Oncology Diagnostics Market, By Cancer Type – Lung Cancer (2020–2027) (USD Million)
Table 18 Global Precision Oncology Diagnostics Market, By Cancer Type – Lung Cancer (2028–2034) (USD Million)
Table 19 Global Precision Oncology Diagnostics Market, By Cancer Type – Colorectal Cancer (2020–2027) (USD Million)
Table 20 Global Precision Oncology Diagnostics Market, By Cancer Type – Colorectal Cancer (2028–2034) (USD Million)
Table 21 Global Precision Oncology Diagnostics Market, By Cancer Type – Others (2020–2027) (USD Million)
Table 22 Global Precision Oncology Diagnostics Market, By Cancer Type – Others (2028–2034) (USD Million)
Table 23 Global Precision Oncology Diagnostics Market, By End-Use – Hospitals & Diagnostic Laboratories (2020–2027) (USD Million)
Table 24 Global Precision Oncology Diagnostics Market, By End-Use – Hospitals & Diagnostic Laboratories (2028–2034) (USD Million)
Table 25 Global Precision Oncology Diagnostics Market, By End-Use – Research Institutes & Academic Centers (2020–2027) (USD Million)
Table 26 Global Precision Oncology Diagnostics Market, By End-Use – Research Institutes & Academic Centers (2028–2034) (USD Million)
Table 27 Global Precision Oncology Diagnostics Market, By End-Use – Pharma & Biotechnology Companies (2020–2027) (USD Million)
Table 28 Global Precision Oncology Diagnostics Market, By End-Use – Pharma & Biotechnology Companies (2028–2034) (USD Million)
Table 29 Global Precision Oncology Diagnostics Market, By End-Use – CROs (2020–2027) (USD Million)
Table 30 Global Precision Oncology Diagnostics Market, By End-Use – CROs (2028–2034) (USD Million)
Table 31 North America Precision Oncology Diagnostics Market (2020–2034) (USD Million)
Table 32 North America Market, By Diagnostic Technology (2020–2034) (USD Million)
Table 33 North America Market, By Cancer Type (2020–2034) (USD Million)
Table 34 North America Market, By End-Use (2020–2034) (USD Million)
Table 35 North America Market – Country-Level Comparison (United States, Canada) (2020–2034) (USD Million)
Table 36 Europe Precision Oncology Diagnostics Market (2020–2034) (USD Million)
Table 37 Europe Market, By Diagnostic Technology (2020–2034) (USD Million)
Table 38 Europe Market, By Cancer Type (2020–2034) (USD Million)
Table 39 Europe Market, By End-Use (2020–2034) (USD Million)
Table 40 Europe Market – Country-Level Comparison (Germany, UK, France, Spain, Italy, Rest of Europe) (2020–2034) (USD Million)
Table 41 Asia-Pacific Market (2020–2034) (USD Million)
Table 42 Asia-Pacific Market, By Diagnostic Technology (2020–2034) (USD Million)
Table 43 Asia-Pacific Market, By Cancer Type (2020–2034) (USD Million)
Table 44 Asia-Pacific Market, By End-Use (2020–2034) (USD Million)
Table 45 Asia-Pacific Market – Country-Level Comparison (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) (2020–2034) (USD Million)
Table 46 Latin America Market (2020–2034) (USD Million)
Table 47 Latin America Market, By Diagnostic Technology (2020–2034) (USD Million)
Table 48 Latin America Market, By Cancer Type (2020–2034) (USD Million)
Table 49 Latin America Market, By End-Use (2020–2034) (USD Million)
Table 50 Latin America Market – Country-Level Comparison (Brazil, Mexico, Argentina, Rest of Latin America) (2020–2034) (USD Million)
Table 51 Middle East & Africa Market (2020–2034) (USD Million)
Table 52 Middle East & Africa Market, By Diagnostic Technology (2020–2034) (USD Million)
Table 53 Middle East & Africa Market, By Cancer Type (2020–2034) (USD Million)
Table 54 Middle East & Africa Market, By End-Use (2020–2034) (USD Million)
Table 55 Middle East & Africa Market – Country-Level Comparison (Saudi Arabia, UAE, Israel, South Africa, Rest of MEA) (2020–2034) (USD Million)
Table 56 Data Validation and Publishing (Secondary Source)
List Of Figures
Fig. 1 Global Precision Oncology Diagnostics Market – Market Snapshot (2020–2034) (USD Million)
Fig. 2 Global Precision Oncology Diagnostics Market – Market Highlights (2020–2034) (USD Million)
Fig. 3 Global Precision Oncology Diagnostics Market – Forecast by Diagnostic Technology (2020–2034) (USD Million)
Fig. 4 Global Precision Oncology Diagnostics Market – Forecast by Cancer Type (2020–2034) (USD Million)
Fig. 5 Global Precision Oncology Diagnostics Market – Forecast by End-Use (2020–2034) (USD Million)
Fig. 6 Global Market – Regional Comparison (2020–2034) (USD Million)
Fig. 7 Global Market – PESTLE Analysis Overview
Fig. 8 Global Market – Value Chain Analysis
Fig. 9 Global Market – Porter’s Five Forces
Fig. 10 North America Market – Overall Snapshot (2020–2034)
Fig. 11 North America Market – By Diagnostic Technology (2020–2034)
Fig. 12 North America Market – By Cancer Type (2020–2034)
Fig. 13 North America Market – By End-Use (2020–2034)
Fig. 14 North America Market – Country-Level Comparison (US & Canada)
Fig. 15 Europe Market – Overall Snapshot (2020–2034)
Fig. 16 Europe Market – By Diagnostic Technology (2020–2034)
Fig. 17 Europe Market – By Cancer Type (2020–2034)
Fig. 18 Europe Market – By End-Use (2020–2034)
Fig. 19 Europe Market – Country-Level Comparison
Fig. 20 Asia-Pacific Market – Overall Snapshot (2020–2034)
Fig. 21 Asia-Pacific Market – By Diagnostic Technology (2020–2034)
Fig. 22 Asia-Pacific Market – By Cancer Type (2020–2034)
Fig. 23 Asia-Pacific Market – By End-Use (2020–2034)
Fig. 24 Asia-Pacific Market – Country-Level Comparison
Fig. 25 Latin America Market – Overall Snapshot (2020–2034)
Fig. 26 Latin America Market – By Diagnostic Technology (2020–2034)
Fig. 27 Latin America Market – By Cancer Type (2020–2034)
Fig. 28 Latin America Market – By End-Use (2020–2034)
Fig. 29 Latin America Market – Country-Level Comparison
Fig. 30 Middle East & Africa Market – Overall Snapshot (2020–2034)
Fig. 31 Middle East & Africa Market – By Diagnostic Technology (2020–2034)
Fig. 32 Middle East & Africa Market – By Cancer Type (2020–2034)
Fig. 33 Middle East & Africa Market – By End-Use (2020–2034)
Fig. 34 Middle East & Africa Market – Country-Level Comparison
Fig. 35 Global Market – Key Company Market Share Analysis (%)
Fig. 36 Global Market – Competitive Positioning Matrix
Fig. 37 Our Research Practice – Research Approach Flow
Fig. 38 Secondary Source Analysis Framework
Fig. 39 Primary Source Interview Methodology
Fig. 40 Data Triangulation Process
Fig. 41 Our Research Process Overview
Research Methodology
Primary and Secondary Research
In order to understand the market in detail we conduct primary and secondary research. We collect as much information as we can from the market experts through primary research. We contact the experts from both demand and supply side and conduct interviews to understand the actual market scenario. In secondary research, we study and gather the data from various secondary sources such as company annual reports, press releases, whitepapers, paid databases, journals, and many other online sources. With the help of the primary interviews, we validate the data collected from secondary sources and get a deep understanding on the subject matter. Post this our team uses statistical tools to analyses the data to arrive at a conclusion and draft it in presentable manner.
Market Size Estimations
Understanding and presenting the data collected is a crucial task. Market sizing is a critical part of the data analysis and this task is performed by using Top-down and bottom-up approaches. In this process, we place different data points, market information and industry trends at a suitable space. This placement helps us presume the estimated & forecast values for coming few years. We use several mathematical and statistical models to estimate the market sizes of different countries and segments. Each of this is further added up to outline the total market. These approaches are individually done on regional/country and segment level.
Data Triangulation
As we arrive at the total market sizes, the market is again broken down into segments and subsegments. This process is called as data triangulation and is implementable wherever applicable. This step not only helps us conclude the overall market engineering process, but also gives an assurance on accuracy of the data generated. The data is triangulated based on studying the market trends, various growth factors, and aspects of both demand and supply side.
